Articles On IDT Australia (ASX:IDT)

Cannabis shares were considered a fad for a while. Now, they’ve proved they’re here to stay. As the Australian medicinal cannabis industry grows, ASX cannabis companies are refining their strategies. While some are focused on cultivation a...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks and of those which were trading on Tuesday, 66 were in positive territory over the last fortnight, 18 were flat and 47 saw t...

Australian cannabis developer Cann Group (ASX: CAN) has signed two agreements for the supply of medicinal cannabis-formulated oil and dried flower products to markets in the United Kingdom and European Union. The first deal is with UK-based...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve keen keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Tom Bleakley, BW Equities BUY RECOMMENDATIONS IDT Australia (IDT) Chart: Share price over the year IDT is an Australian pharmaceutical company, with extensive experience in developing and producing high potency and high containment products...

Before 1942, Australia hadn’t fully come to terms with what a world war would require it to do. By the end of 1942, after the Japanese Imperial airforce bombed Darwin, the country was a very different place. It had gone from a tiny populati...

As with the early medical cannabis plays, a cluster of ASX-listed stocks has wasted little time attaching itself to the ‘c’ word. We’re talking of course about the coronavirus COVID-19 but sadly not another ‘c’ word: cure. Or not yet. Accor...

Reporting season wrapped up last week with the S&P/ASX 200 Index (INDEXASX: XJO) falling more than 10% from recent highs. As fears around the spread of coronavirus escalated, the contagion of fear infected markets, prompting a major c...

The Cann Group Ltd (ASX: CAN) share price has plunged 5.15% in early trade after the cannabis cultivator released its half year results last night. Cann Group reported a loss for the half year, but is seeking to transition to near-term pro...

Following a 30 per cent gain in 2019, the S&P/ASX Emerging Companies index – which measures overall performance of the ASX microcap sector — moved another 3 per cent higher in January. Of the sub-$400m market cap companies on our list,...

ASX cannabis shares endured a tough 2019, as investors cooled on the latest investing trend. However, some of the biggest listed groups have bounced back in January and are up as much as 100% this year. Here’s why 3 of the biggest names in...

The All Ordinaries index has started 2020 in an exceptionally positive fashion. The year may be just a touch over four weeks old, but the index has already carved out a gain of 5.8%. Whilst this is impressive, a number of shares on the ind...

Shares in Cann Group Ltd (ASX: CAN) rose to fresh highs for the year yesterday. The Cann Group share price rose 22.55% during the day to close at $1.68, up significantly from Friday’s close of $1.36. The Cann Group share price has since f...

Only one prescription for medical marijuana has been issued by a doctor in the Northern Territory, according to Minister for Health Natasha Fyles. In a submission to the Senate inquiry into barriers to patient access to marijuana, Fyles sai...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

The Cann Group Ltd (ASX: CAN) share price was on form again on Monday and recorded another strong gain. The medicinal cannabis company’s shares raced 13% higher to end the day at $1.07. This latest gain means that Cann Group’s shares have...

As the world learns tasty cannabis edibles might not be the safest of munchies, Australian investors have served up 19 small cap cannabis stocks as gainers on the ASX. Cannabis edibles are legal in some US states and Canada and just one pro...

Cann Group (CAN) and IDT Australia (IDT) have announced that GMP extraction activities are underway for the first batches of medicinal cannabis resin The extracted resin will be used as an active pharmaceutical ingredient to produce GMP me...

Cann Group (ASX: CAN) and IDT Australia (ASX: IDT) are closer to producing their first medicinal cannabis products with GMP extraction activities now underway. Once extracted, the resin will be used as an active pharmaceutical ingredient fo...

Cann Group’s (ASX: CAN) manufacturer has started making cannabis resin from the company’s plants, and it should be ready for sale by March. The resin needs to be tested for stability before being sold as oil and as an active pharmaceutical...

07 Jan 2020 - The Cann Group (ASX:CAN) and IDT Australia (ASX:IDT) have jointly announced that GMP extraction activities are underway for the first batches of medicinal cannabis re…

The Cann Group Ltd (ASX: CAN) share price has returned from its trading halt and rocketed higher. In morning trade the cannabis company’s shares are up 25% to $1.26. Why is the Cann Group share price rocketing higher on Tuesday? Investors...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Few people are at their desks in the week between Christmas and new year, which means it’s a prime dumping period for companies wanting to hide bad news. But there’s always someone who draws the short straw in a newsroom and this year it wa...

The Cann Group Ltd (ASX: CAN) share price was the best performer on the All Ordinaries index on Monday before being placed in a trading halt. The cannabis company’s shares were up as much as 28% to $1.03 at one stage today. And were 25.5%...

This year was a difficult one for ASX cannabis shares as well as cannabis stocks globally with share prices worldwide retreating from previous highs. In Australia the medical marijuana industry remains in its infancy. Nonetheless, the init...

Invion (ASX:IVX) may have a new Chinese partner to help get its cosmetics business off the ground. The company told shareholders this morning it signed an MoU with Pavay Biotech, an established provider of dermatology treatment products in...

Cannabis industry is booming at a rapid pace, with several governments creating opportunities for investors by legalising recreational and medicinal cannabis. With increasing legalisation of cannabis, number of investors and entrepreneurs j...

The AusCann Group Holdings Ltd (ASX: AC8) share price certainly was out of form on Thursday. The medicinal cannabis company’s shares were the worst performers on the All Ordinaries with a decline of 13% to 23.5 cents. Why did the AusCann s...

In afternoon trade the S&P/ASX 200 index is on course to finish the day lower. At the time of writing the benchmark index is down 0.1% to 6,843.6 points. Four shares that have not let that hold them back today are listed below. Here’s...

The new COO has more than 30 years’ experience in the pharmaceutical industry in Australia and the UK including roles at PCI Clinical Services, LEO Pharma, IDT Australia, GlaxoSmithKline and Pfizer.

Cann Global (ASX:CGB) has become the second small cap to enter the African cannabis market. It is a market that is estimated to reach $7.1 billion by 2023 although is only legal in three countries including South Africa, Zimbabwe and Lesoth...

Cann Group (ASX: CAN) has confirmed the first commercial medicinal cannabis product to be made at Cann’s Australian-based cultivation operations has been packed by IDT Australia (ASX: IDT) in preparation for commercial release in the new ye...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

In morning trade the Cann Group Ltd (ASX: CAN) share price is rocketing higher. At the time of writing the cannabis company’s shares are up 20% to 51 cents. Why is the Cann Group share price rocketing higher? Investors have been buying Can...

In the global medical cannabis market scenario, Australian cannabis market is the fastest one growing in leaps and bounds. The use of cannabis as a pharmaceutical product for the therapy in severe medical conditions such as Alzheimer’s dise...

Lately, cannabis stocks in the US have come under pressure, following the rising death toll from vaping that reached 42 so far in 2019, according to media reports. Meanwhile, in Canada, Canopy Growth unveiled that returned cannabis oil prod...

Cannabis Industry The Australian cannabis industry is the newest and the most dynamic sector after the legalization of cannabis for medicinal as well as recreational purposes. The cannabis industry refers to the activities and all the profe...

The Cann Group Ltd (ASX: CAN) share price is having a rare positive day of trade. In morning trade the cannabis company’s shares are up 4% to $1.05. This has reduced its one-month decline to approximately 30%. Why is the Cann Group share p...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

Cannabis industry in Australia is growing at a fast pace, and government authorities across the country are creating a lot of prospects for investors by legalising medicinal cannabis. Moreover, it is being assumed that the Australia cannabi...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

Shares in biotech Orthocell (ASX:OCC) are on the move again today after the company reported further positive results for its CelGro technology. Patients who completed the company’s CelGro tendon regeneration trial reported they had regaine...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

Cannabis: An Overview The cannabis industry is booming at a rapid pace with governments across the globe creating the opportunities for investors by legalising recreational and medicinal cannabis. Legalisation of cannabis by government auth...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...